Neyssa Marina

Publication Details

• Children's Oncology Group's 2013 blueprint for research: Bone tumors.

  Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N. Pediatr Blood Cancer. 2013; 60 (6): 1009-15

  In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves survival with localized ES. In osteosarcoma a large international trial investigating the addition of ifosfamide/etoposide or interferon to standard therapy has completed accrual. For ES an ongoing trial explores the addition of cyclophosphamide/topotecan to interval-compressed chemotherapy. Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma. Pediatr Blood Cancer 2013; 60: 1009-1015. © 2012 Wiley Periodicals, Inc.

  PubMedID: 23255238